TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20886571
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER alone (4 mg QD)
Study: 20886571
Drug: Low-dose pregabalin/tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose pregabalin/tolterodine ER (75 mg BID/2 mg QD)
Study: 19723121
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tonabersat
Study: 19723121
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tonabersat
Study: 19723121
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sumatriptan (positive control)
Study: 17368154
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg daily, 5 mg for children younger than 12 months) for mean 484.7 days
Study: 12013585
Drug: Dysport 500
Normalized name: Dysport 500 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport 500 units (open phase treatment)
Study: 12013585
Drug: Placebo (open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (open phase treatment)
Study: 9141920
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid (100 mg/kg, followed by 10 mg.kg‐1.h‐1)
Study: 8201089
Drug: Fluid infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid infusion alone (Group non-HD)
Study: 3322955
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg plus pirenzepine 100 mg daily
Study: 27173813
Drug: Sipjeondaebo-tang (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipjeondaebo-tang (3 g, 3 times a day for 4 weeks)
Study: 24987061
Drug: Cetuximab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (in combination with CAPOX)
Study: 23342566
Drug: 1.23% APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% APF gel for 1 minute
Study: 23342566
Drug: 1.23% APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% APF gel for 4 minutes
Study: 23342566
Drug: 1% TiF4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% TiF4 solution for 1 minute
Study: 18156640
Drug: Olanzapine, risperidone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine, risperidone, and typical antipsychotics
Study: 12865605
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of citicoline twice per day
Study: 10225070
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with buprenorphine 0.15 mg
Study: 10225070
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural analgesia (LEA) with buprenorphine 0.15 mg
Study: 1909239
Drug: Loreclezole (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loreclezole (targeted plasma level of 1-2 mg/l)
Study: 28381307
Drug: Antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drugs after ICH
Study: 24107831
Drug: Levobupivacaine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 5 mg/mL, 45 mL
Study: 24107831
Drug: Levobupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 7.5 mg/mL, 30 mL
Study: 24107831
Drug: Levobupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 7.5 mg/mL mixed with 0.9% NaCl, 30 mL
Study: 11575416
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg kg(‐1) to a maximum of 25 mg
Study: 11575416
Drug: Ondansetron 100
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 100 microg kg(‐1) to a maximum of 4 mg
Study: 2686409
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg twice daily for 14 days
Study: 2686409
Drug: Ampicillin 500
Normalized name: ampicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 500 mg four times a day for 14 days
Study: 28801309
Drug: Cold-pressed turnip
Normalized name: LEMON OIL, COLD PRESSED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-pressed turnip rapeseed oil (CPTRO) 35 mL for 6-8 weeks
Study: 28801309
Drug: Butter 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter 37.5 g for 6-8 weeks
Study: 24398758
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m² for 21 days)
Study: 24398758
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m² for 21 days)
Study: 20178093
Drug: Cannabis extract
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis extract (20 mg THC)
Study: 18289159
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with anthelmintic drugs
Study: 14639535
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 200 mg once daily
Study: 14639535
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 25 mg once daily
Study: 14639535
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) 100 mg once daily
Study: 14639535
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (3TC) 150 mg 2 times/day
Study: 27211522
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone 20 mg
Study: 27211522
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone 20 mg plus naltrexone 2.4 mg (simulated crushed ALO-02)
Study: 27211522
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride for injection)
Study: 17414980
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg intraoperative dose)
Study: 11865837
Drug: Pentoxifylline (PXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PXF) 400 mg three times daily
Study: 7776987
Drug: 240 ml
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 ml of lactose-hydrolyzed milk containing 2 percent fat
Study: 7776987
Drug: 240 ml
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 ml of milk containing 2 percent fat and sweetened with aspartame
Study: 2137976
Drug: Nafarelin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin, 200 micrograms twice daily
Study: 2137976
Drug: Danazol, 200
Normalized name: Danazol, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol, 200 mg twice daily
Study: 25863797
Drug: Daily maximum
Normalized name: GNP One Daily Maximum Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily maximum respiratory rate (maxRR)
Study: 25863797
Drug: Daily median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily median respiratory rate (medRR)
Study: 25863797
Drug: Daily minimum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily minimum respiratory rate (minRR)
Study: 23261207
Drug: PHAROS Vitesse
Normalized name: Vitespen
DrugBank: Vitespen (DB06400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHAROS Vitesse neurovascular balloon-expandable stent system plus medical therapy
Study: 20868456
Drug: Southern regular
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern regular implants and standard ball attachments (control)
Study: 20868456
Drug: Southern 8-mm-wide
Normalized name: SOUTHERN FLOUNDER
DrugBank: Flounder (DB10531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern 8-mm-wide implants and large ball attachments
Study: 20868456
Drug: Neoss regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoss regular implants and Locator attachments
Study: 20868456
Drug: Southern 8-mm-wide
Normalized name: SOUTHERN FLOUNDER
DrugBank: Flounder (DB10531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern 8-mm-wide implants and large ball attachments and Neoss regular implants and Locator attachments
Study: 16705849
Drug: Composite sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite sulfur (tablet) moxibustion plus SASP and MTX
Study: 11281583
Drug: 0.2 mg/ml
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/ml MMC applied for 5 minutes
Study: 11281583
Drug: 0.5 mg/ml
Normalized name: urea 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/ml MMC applied for 5 minutes
Study: 9207749
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg + 6 x 10(8) KML
Study: 9207749
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg + 5 x 10(7) KML
Study: 9207749
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg + 5 x 10(6) KML
Study: 9207749
Drug: BCG 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 0.1 mg
Study: 2908765
Drug: Lidamidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidamidine (20 mg p.o.)
Study: 2908765
Drug: Idazoxan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idazoxan (20 mg p.o.)
Study: 27399998
Drug: No medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medications (Control)
Study: 19122958
Drug: 80 percent
Normalized name: Blended spread 70 to 80 percent fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 percent phenol solution
Study: 8214494
Drug: Intra-arterial regional
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial regional analgesia with lignocaine 0.5%, 1.5 mg.kg‐1
Study: 8214494
Drug: Intravenous regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous regional analgesia with lignocaine 0.5%, 3.0 mg.kg‐1
Study: 3440240
Drug: Radical orchidectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical orchidectomy and chemotherapy for Group I patients
Study: 3440240
Drug: Orchidectomy, chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchidectomy, chemotherapy, and radiation therapy for Group II patients
Study: 3440240
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for patients with distant metastases at diagnosis
Study: 3440240
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment for all 95 children
Study: 25622243
Drug: Ibuprofen (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1.2 g administered 1 hour before the second tlim trial)
Study: 25622243
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose administered 1 hour before the second tlim trial)
Study: 21775979
Drug: Duloxetine (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (14 days treatment)
Study: 16540949
Drug: Urinary trypsin
Normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary trypsin inhibitor (5000 units/kg intravenous)
Study: 12656696
Drug: Omeprazole-based triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-based triple therapy
Study: 7490894
Drug: Self-administered alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered alfentanil via a patient controlled infusion pump
Study: 7490894
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving alfentanil infusion titrated by anesthesiologists
Study: 29186989
Drug: EPVL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPVL plus 0.4 mg oral tamsulosin daily (n=236)
Study: 29186989
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin PO qd (n=222)
Study: 24284002
Drug: Combined KMC
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined KMC and 24% oral sucrose
Study: 24284002
Drug: 24% oral
Normalized name: Entero VU, 24% oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% oral sucrose alone
Study: 21827441
Drug: 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mcg/kg dexmedetomidine in 100 ml of normal saline over 10 min; 1 mcg/kg/h dexmedetomidine infusion during surgery
Study: 21827441
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of normal saline over 10 min; 1 ml/kg/h normal saline infusion during surgery
Study: 17873492
Drug: Bosentan (8-125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (8-125 mg b.i.d.)
Study: 12424933
Drug: Deferiprone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (75 mg/kg/day in 12 hourly divided doses)
Study: 12424933
Drug: Standard quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard quinine and doxycycline therapy with placebo
Study: 8955576
Drug: Nasal corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal corticosteroid treatment
Study: 1834440
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of ANF 100 micrograms
Study: 1834440
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of ANF 50 micrograms at 1.67 micrograms/min for 30 min
Study: 29793446
Drug: Propranolol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administration
Study: 14658256
Drug: Indomethacin administration
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin administration
Study: 26096582
Drug: Robot-assisted intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted intervention with Paro (30 minutes twice a week for 12 weeks)
Study: 24924267
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid spray (two pumps, three times daily for 7 days)
Study: 24924267
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride spray (two pumps, three times daily for 7 days)
Study: 19317300
Drug: Prolonged heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged heparin infusion
Study: 19317300
Drug: No post-procedural
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No post-procedural heparin (control group)
Study: 17503991
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean endpoint dose = 460 ± 88 mg/day)
Study: 6841187
Drug: Remotely controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely controlled high-dose-rate intracavitary radiotherapy (30 Gy for high-dose-rate group by 3 fractions with a once a week schedule)
Study: 6841187
Drug: Manual afterloading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual afterloading low-dose-rate therapy (40-60 Gy with one or two fractions)
Study: 6841187
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (high-dose-rate and low-dose-rate)
Study: 30620767
Drug: Clinical trials
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trials with new anticancer biological agents
Study: 30620767
Drug: Clinical trials
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trials with immunotherapeutic drugs
Study: 31676222
Drug: Odanacatib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (50 mg once per week)
Study: 26564281
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100-200mg daily)
Study: 26564281
Drug: Letrozole (2.5-5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5-5mg daily)
Study: 16428551
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg
Study: 7931231
Drug: Deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl (10 mg per day for 12 weeks)
Study: 3146506
Drug: Oral co-dergocrine
Normalized name: co-dergocrine mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-dergocrine (8.0 mg)
Study: 3146506
Drug: Intravenous co-dergocrine
Normalized name: co-dergocrine mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous co-dergocrine (0.9 mg)
Study: 3146506
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and oral doses
Study: 31977270
Drug: D-index-guided early
Normalized name: MAGNI-GUIDE (B-D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-index-guided early antifungal therapy (DET)
Study: 31977270
Drug: Empiric antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antifungal therapy (EAT)
Study: 26630216
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 or 20 mg daily
Study: 26630216
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 or 20 mg daily
Study: 26630216
Drug: Lercanidipine-Enalapril combination
Normalized name: enalapril and lercanidipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine-Enalapril combination treatment
Study: 25519464
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (58.5 mg/mL)
Study: 25519464
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (9 mg/mL)
Study: 20674480
Drug: 7% carbon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% carbon dioxide inhalation
Study: 10746484
Drug: Trandolapril 4
Normalized name: trandolapril 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 4 mg daily
Study: 8770673
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy aimed to correct CA, N=15
Study: 1579938
Drug: Piroxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (40 mg preoperatively, 40 mg on the day of surgery, 20 mg on days 1 and 2)
Study: 31417163
Drug: Neuraminidase inhibitors
Normalized name: Neuraminidase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuraminidase inhibitors (NAIs)
Study: 27605365
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (SC) + Text Messaging (TM) + Adherence-focused Behavioral Therapy (ABT)
Study: 21193066
Drug: Community-wide isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Community-wide isoniazid preventive therapy (IPT) offered to all employees
Study: 20214205
Drug: 20% Albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Albumin 100 ml every 12 hours
Study: 20214205
Drug: 6% hydroxyethylstarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethylstarch 250 ml every 6 hours
Study: 16632238
Drug: Gliclazide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (160 mg daily for 4 weeks)
Study: 16632238
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg daily for 4 weeks)
Study: 16632238
Drug: Gliclazide and
Normalized name: Gliclazide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide and Glibenclamide (both treatments)
Study: 12730416
Drug: -ISO (soy
Approvals — FDA: no, EMA: no, PMDA: no
Description: -ISO (soy protein with 3 mg isoflavones)
Study: 1689679
Drug: Surgical biliary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical biliary bypass followed by synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in Group 1.
Study: 1689679
Drug: Synchronous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in Group 2.
Study: 1689679
Drug: Synchronous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in both groups.
Study: 6987582
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg potassium penicillin or erythromycin ethylsuccinate q.i.d.
Study: 29069153
Drug: Codeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (30 mg) plus acetaminophen (500 mg), every 4 h, for 3 days
Study: 29069153
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride (37.5 mg) plus acetaminophen (500 mg), every 4 h, for 3 days
Study: 21982651
Drug: Darapladib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib (160 mg enteric-coated tablet daily)
Study: 8779124
Drug: Long term
Normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long term steroid treatment (group L) for at least 18 months
Study: 8779124
Drug: Selective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective treatment (group S) reserved for symptoms or deteriorating lung function
Study: 6859300
Drug: Abstinence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence therapy
Study: 31520576
Drug: Aripiprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10 mg single oral dose)
Study: 26966829
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping (KT) in combination with counseling and jaw exercise
Study: 25134002
Drug: Caffeine 3
Normalized name: caffeine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3 mg·kg body mass
Study: 25134002
Drug: Caffeine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 4.5 mg·kg body mass
Study: 14715864
Drug: Glibenclamide (10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (10.5 mg)